# US 2001/0027216 A1 · Method for preventing hormone induced adverse effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027216 A1
- Document ID: US20010027216A1
- Status: Published application
- Kind: A1
- Application number: 09/799,140
- Filed: 2001-03-05
- Published: 2001-10-04
- Earliest claimed: 2000-03-29
- Inventors: Joseph Levy; Yoav Sharoni
- Web page: https://patentgrep.com/patent/US20010027216A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/015: carbocyclic
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 5/30: Oestrogens
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/12: for climacteric disorders
- A61P 15/18: Feminine contraceptives
- A61P 19/10: for osteoporosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for preventing the adverse effects which may be associated with the administration of at least one hormone to a subject without detectable cancer comprising administering to such subject at least one carotenoid. The invention further provides a method for preventing a variety of adverse effects associated with the administration of hormones, including, for example, an increased risk for developing cancer. The invention further provides a method for preventing adverse effects without inhibiting the beneficial activity of the hormone. The invention further provides a method for preventing the adverse effects associated with administration of estrogen and/or progestin in hormone replacement therapy without inhibiting the beneficial activity of such hormone. The invention further provides a method for preventing the adverse effects associated with the administration of phytoestrogens. The invention further provides a method for preventing adverse effects associated with the administration of phytoestrogens without inhibiting the beneficial activity of such hormone.

## Claims

### Claim 1

A method of preventing adverse effects which may result from the administration of at least one hormone to a subject without detectable cancer comprising administering to said subject at least one carotenoid in an amount from about 2 to about 10 mg per day.

### Claim 2 (depends on 1)

The method of claim 1 in which the carotenoid is administered in an amount from about 2 to about 6 mg per day.

### Claim 3 (depends on 1)

The method of claim 1 in which the carotenoid is administered in an amount of about 2 mg per day.

### Claim 4

A method of preventing adverse effects which may result from the administration of at least one hormone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount of about 2 mg per day.

### Claim 5

A method of preventing adverse effects which may result from the administration of at least one hormone to a subject without detectable cancer comprising administering to said subject at least one carotenoid selected from the group consisting of alpha-carotene, beta-carotene and cryptoxanthin in an amount of about 2 mg per day.

### Claim 6 (depends on 1, 4, 5)

The method of any of claims 1, 4 or 5 wherein said carotenoid is in an amount sufficient to cause an effective serum concentration of said carotenoid of up to about 1.5 μM.

### Claim 7 (depends on 1, 4, 5)

The method of any of claims 1, 4 or 5 wherein said hormone comprises phytoestrogen, nonsteroidal estrogen, or a mixture thereof.

### Claim 8 (depends on 1, 4, 5)

The method of any of claims 1, 4 or 5 wherein said hormone comprises steroidal estrogen, progestin, or a mixture thereof.

### Claim 9 (depends on 1, 4)

The method of claim 1 or 4 wherein said carotenoid is lycopene.

### Claim 10 (depends on 1, 4)

The method of claim 1 or 4 wherein said carotenoid is selected from the group consisting of lycopene, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, and astaxantine.

### Claim 11 (depends on 1, 2, 3, 4)

The method of any of claims 1-4 wherein said carotenoid comprises a mixture of lycopene and phytoene.

### Claim 12 (depends on 1, 2, 3, 4)

The method of any of claims 1-4 wherein said carotenoid comprises a mixture of lycopene and phytofluene.

### Claim 13 (depends on 1, 2, 3, 4)

The method of any of claims 1-4 wherein said carotenoid comprises a mixture of lycopene, phytoene and phytofluene.

### Claim 14 (depends on 1, 4, 5)

The method of any of claims 1, 4 or 5 wherein said carotenoid is co-administered with said hormone in a composition separate from said hormone.

### Claim 15 (depends on 1, 4, 5)

The method of any of claims 1, 4 or 5 wherein said carotenoid is co-administered with said hormone in a composition further comprising said hormone.

### Claim 16

A method of preventing adverse effects which may result from the administration of at least one hormone selected from group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount from about 2 to about 10 mg per day without inhibiting the beneficial activity of said hormone.

### Claim 17

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount from about 2 to about 6 mg per day without inhibiting the beneficial activity of said hormone.

### Claim 18

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount of about 2 mg per day without inhibiting the beneficial activity of said hormone.

### Claim 19

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid selected from the group consisting of alpha-carotene and cryptoxanthin in an amount of about 2 mg per day without inhibiting the beneficial activity said hormone.

### Claim 20 (depends on 16, 17, 18)

The method of any of claims 16-18 wherein said carotenoid is selected from the group consisting of lycopene, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, and astaxantine.

### Claim 21 (depends on 16, 17, 18)

The method of any of claims 16-18 wherein said carotenoid comprises a mixture of lycopene and phytoene.

### Claim 22 (depends on 16, 17, 18)

The method of any of claims 16-18 wherein said carotenoid comprises a mixture of lycopene and phytofluene.

### Claim 23 (depends on 16, 17, 18)

The method of any of claims 16-18 wherein said carotenoid comprises a mixture of lycopene, phytoene and phytofluene.

### Claim 24 (depends on 16, 17, 18, 19)

The method of any of claims 16-19 wherein said carotenoid is co-administered with said hormone in a composition separate from said hormone.

### Claim 25 (depends on 16, 17, 18, 19)

The method of any of claims 16-19 wherein said carotenoid is co-administered with said hormone in a composition further comprising said hormone.
